PYXS Quote, Financials, Valuation and Earnings

Climb Bio has a net margin of -20.17% compared to Pyxis Oncology's net margin of --. Pyxis Oncology's return on equity of -- beat Climb Bio's return on equity of --.

Pyxis Oncology has a consensus price target of $6.20, signalling upside risk potential of 416.67%. On the other hand Climb Bio has an analysts' consensus of $10.00 which suggests that it could grow by 719.67%. Given that Climb Bio has higher upside potential than Pyxis Oncology, analysts believe Climb Bio is more attractive than Pyxis Oncology.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Climb Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Climb Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology pays -- of its earnings as a dividend. Climb Bio pays out -- of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are larger than Climb Bio quarterly revenues of --. Pyxis Oncology's net income of -$21.2M is lower than Climb Bio's net income of -$20.8M. Notably, Pyxis Oncology's price-to-earnings ratio is -- while Climb Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus -- for Climb Bio. Usually stocks with elevated PS ratios are considered overvalued.

Mersana Therapeutics has a net margin of -20.17% compared to Pyxis Oncology's net margin of -875.93%. Pyxis Oncology's return on equity of -- beat Mersana Therapeutics's return on equity of -533.43%.

Pyxis Oncology has a consensus price target of $6.20, signalling upside risk potential of 416.67%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.29 which suggests that it could grow by 1071.28%. Given that Mersana Therapeutics has higher upside potential than Pyxis Oncology, analysts believe Mersana Therapeutics is more attractive than Pyxis Oncology.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.945%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are larger than Mersana Therapeutics quarterly revenues of $2.8M. Pyxis Oncology's net income of -$21.2M is higher than Mersana Therapeutics's net income of -$24.1M. Notably, Pyxis Oncology's price-to-earnings ratio is -- while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 1.33x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -20.17% compared to Pyxis Oncology's net margin of -436.62%. Pyxis Oncology's return on equity of -- beat Sutro Biopharma's return on equity of -322.47%.

Pyxis Oncology has a consensus price target of $6.20, signalling upside risk potential of 416.67%. On the other hand Sutro Biopharma has an analysts' consensus of $3.26 which suggests that it could grow by 255.7%. Given that Pyxis Oncology has higher upside potential than Sutro Biopharma, analysts believe Pyxis Oncology is more attractive than Sutro Biopharma.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.488%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are smaller than Sutro Biopharma quarterly revenues of $17.4M. Pyxis Oncology's net income of -$21.2M is higher than Sutro Biopharma's net income of -$76M. Notably, Pyxis Oncology's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 1.13x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -20.17% compared to Pyxis Oncology's net margin of -479.24%. Pyxis Oncology's return on equity of -- beat Voyager Therapeutics's return on equity of -26.82%.

Pyxis Oncology has a consensus price target of $6.20, signalling upside risk potential of 416.67%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.00 which suggests that it could grow by 477.94%. Given that Voyager Therapeutics has higher upside potential than Pyxis Oncology, analysts believe Voyager Therapeutics is more attractive than Pyxis Oncology.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.041%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are larger than Voyager Therapeutics quarterly revenues of $6.5M. Pyxis Oncology's net income of -$21.2M is higher than Voyager Therapeutics's net income of -$31M. Notably, Pyxis Oncology's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 2.36x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.